Ann: Results of Phase 2 trial in moderate to severe TBI-NEU.AX, page-25

from the announcement this morning: "The safety results from INTREPID, which was the primary endpoint of the trial, identified no treatment related or dose-dependent trends in adverse events or laboratory results". So the end point of this PII trial was to prove the safety of Trofinetide rather than its efficacy. And then Larry Glass says this: “Combined with the safety information from the Rett and Fragile X syndrome trials, the results from the INTREPID trial support the use of considerably higher doses in TBI patients. We have also made advances in the use of biomarkers and other measures of baseline severity that would improve the design and analysis of a future trial. After further analysis, we will determine with our U.S. Army colleagues the best way forward for Trofinetide in brain injury.” His comments were supported by his colleague from the US army. It seems that the US Army is willing to persist with further examination of these test results, and be involved in further trials at higher dose rates. It will take a few years, but I am a patient man, and still believe NEU is worth holding on to. If it drops much more in price it could be good buying for the years ahead.